Show simple item record

dc.contributor.authorLuo, Yuan
dc.contributor.authorArita, Kyouhei
dc.contributor.authorBhatia, Monica
dc.contributor.authorKnuckley, Bryan
dc.contributor.authorLee, Young-Ho
dc.contributor.authorStallcup, Michael R.
dc.contributor.authorSato, Mamoru
dc.contributor.authorThompson, Paul R
dc.date2022-08-11T08:11:00.000
dc.date.accessioned2022-08-23T17:28:24Z
dc.date.available2022-08-23T17:28:24Z
dc.date.issued2006-10-03
dc.date.submitted2015-06-05
dc.identifier.citationBiochemistry. 2006 Oct 3;45(39):11727-36. <a href="http://dx.doi.org/10.1021/bi061180d">Link to article on publisher's site</a>
dc.identifier.issn0006-2960 (Linking)
dc.identifier.doi10.1021/bi061180d
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50072
dc.description<p>At the time of publication, Paul Thompson was not yet affiliated with UMass Medical School.</p>
dc.description.abstractProtein arginine deiminase 4 (PAD4) is a transcriptional coregulator that catalyzes the calcium-dependent conversion of specific arginine residues in proteins to citrulline. Recently, we reported the synthesis and characterization of F-amidine, a potent and bioavailable irreversible inactivator of PAD4. Herein, we report our efforts to identify the steric and leaving group requirements for F-amidine-induced PAD4 inactivation, the structure of the PAD4-F-amidine x calcium complex, and in vivo studies with N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (Cl-amidine), a PAD4 inactivator with enhanced potency. The PAD4 inactivators described herein will be useful pharmacological probes in characterizing the incompletely defined physiological role(s) of this enzyme. In addition, they represent potential lead compounds for the treatment of rheumatoid arthritis because a growing body of evidence supports a role for PAD4 in the onset and progression of this chronic autoimmune disorder.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17002273&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808342/
dc.subjectAmidines
dc.subjectArginine
dc.subjectArthritis, Rheumatoid
dc.subjectCalcium
dc.subjectChronic Disease
dc.subjectCitrulline
dc.subjectEnzyme Activation
dc.subjectEnzyme Inhibitors
dc.subjectHumans
dc.subjectHydrocarbons, Fluorinated
dc.subjectHydrolases
dc.subjectMolecular Probes
dc.subjectProtein Processing, Post-Translational
dc.subjectProtein Structure, Tertiary
dc.subjectBiochemistry
dc.subjectEnzymes and Coenzymes
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectTherapeutics
dc.titleInhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization
dc.typeJournal Article
dc.source.journaltitleBiochemistry
dc.source.volume45
dc.source.issue39
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/thompson/78
dc.identifier.contextkey7185890
html.description.abstract<p>Protein arginine deiminase 4 (PAD4) is a transcriptional coregulator that catalyzes the calcium-dependent conversion of specific arginine residues in proteins to citrulline. Recently, we reported the synthesis and characterization of F-amidine, a potent and bioavailable irreversible inactivator of PAD4. Herein, we report our efforts to identify the steric and leaving group requirements for F-amidine-induced PAD4 inactivation, the structure of the PAD4-F-amidine x calcium complex, and in vivo studies with N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (Cl-amidine), a PAD4 inactivator with enhanced potency. The PAD4 inactivators described herein will be useful pharmacological probes in characterizing the incompletely defined physiological role(s) of this enzyme. In addition, they represent potential lead compounds for the treatment of rheumatoid arthritis because a growing body of evidence supports a role for PAD4 in the onset and progression of this chronic autoimmune disorder.</p>
dc.identifier.submissionpaththompson/78
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages11727-36


This item appears in the following Collection(s)

Show simple item record